Selective Visualization of Cyclooxygenase-2 in Inflammation and Cancer by Targeted Fluorescent Imaging Agents

被引:141
|
作者
Uddin, Md. Jashim [3 ,4 ]
Crews, Brenda C. [3 ,4 ]
Blobaum, Anna L. [3 ,4 ]
Kingsley, Philip J. [3 ,4 ]
Gorden, D. Lee [5 ]
McIntyre, J. Oliver [5 ]
Matrisian, Lynn M. [5 ]
Subbaramaiah, Kotha [6 ]
Dannenberg, Andrew J. [6 ]
Piston, David W. [1 ,2 ]
Marnett, Lawrence J. [1 ,3 ,4 ]
机构
[1] Vanderbilt Univ, Med Ctr, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Dept Phys & Astron, Sch Med, Nashville, TN 37232 USA
[3] Vanderbilt Inst Chem Biol, AB Hancock Jr Mem Lab Canc Res, Dept Biochem, Ctr Mol Toxicol, Nashville, TN USA
[4] Vanderbilt Inst Chem Biol, AB Hancock Jr Mem Lab Canc Res, Dept Chem & Pharmacol, Ctr Mol Toxicol, Nashville, TN USA
[5] Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN USA
[6] Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA
关键词
GROWTH-FACTOR RECEPTOR; IN-VIVO EVALUATION; HUMAN COLON-CANCER; SUBCELLULAR-LOCALIZATION; COX-2; EXPRESSION; PET TRACER; INHIBITION; SYNTHASE-1; PROTEIN; TUMORS;
D O I
10.1158/0008-5472.CAN-09-2664
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Effective diagnosis of inflammation and cancer by molecular imaging is challenging because of interference from nonselective accumulation of the contrast agents in normal tissues. Here, we report a series of novel fluorescence imaging agents that efficiently target cyclooxygenase-2 (COX-2), which is normally absent from cells, but is found at high levels in inflammatory lesions and in many premalignant and malignant tumors. After either i.p. or i.v. injection, these reagents become highly enriched in inflamed or tumor tissue compared with normal tissue and this accumulation provides sufficient signal for in vivo fluorescence imaging. Further, we show that only the intact parent compound is found in the region of interest. COX-2-specific delivery was unambiguously confirmed using animals bearing targeted deletions of COX-2 and by blocking the COX-2 active site with high-affinity inhibitors in both in vitro and in vivo models. Because of their high specificity, contrast, and detectability, these fluorocoxibs are ideal candidates for detection of inflammatory lesions or early-stage COX-2-expressing human cancers, such as those in the esophagus, oropharynx, and colon. Cancer Res; 70(9); 3618-27. (C) 2010 AACR.
引用
收藏
页码:3618 / 3627
页数:10
相关论文
共 50 条
  • [21] Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro
    Fife, RS
    Stott, B
    Carr, RE
    CANCER BIOLOGY & THERAPY, 2004, 3 (02) : 228 - 232
  • [22] Fluorophore-Labeled Cyclooxygenase-2 Inhibitors for the Imaging of Cyclooxygenase-2 Overexpression in Cancer: Synthesis and Biological Studies
    Bhardwaj, Atul
    Kaur, Jatinder
    Wuest, Frank
    Knaus, Edward E.
    CHEMMEDCHEM, 2014, 9 (01) : 109 - 116
  • [23] A novel near-infrared fluorescent probe for monitoring cyclooxygenase-2 in inflammation and tumor
    Zhang, Qi
    Han, Zhihao
    Tao, Ji
    Zhang, Wancun
    Li, Ping
    Tang, Liping
    Gu, Yueqing
    JOURNAL OF BIOPHOTONICS, 2018, 11 (06)
  • [24] Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
    Kurumbail, RG
    Stevens, AM
    Gierse, JK
    McDonald, JJ
    Stegeman, RA
    Pak, JY
    Gildehaus, D
    Miyashiro, JM
    Penning, TD
    Seibert, K
    Isakson, PC
    Stallings, WC
    NATURE, 1996, 384 (6610) : 644 - 648
  • [25] The coxibs, selective inhibitors of cyclooxygenase-2
    Killen, JP
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23): : 1708 - 1708
  • [27] SELECTIVE-INHIBITION OF CYCLOOXYGENASE-2
    KLEIN, T
    NUSING, RM
    PFEILSCHIFTER, J
    ULLRICH, V
    BIOCHEMICAL PHARMACOLOGY, 1994, 48 (08) : 1605 - 1610
  • [28] Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents
    Marnett, LJ
    Kalgutkar, AS
    CURRENT OPINION IN CHEMICAL BIOLOGY, 1998, 2 (04) : 482 - 490
  • [30] Celecoxib: a selective cyclooxygenase-2 inhibitor
    Gandelman, M
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S53 - S53